Most patients with Alzheimer's disease present with amnestic problems; however, a
substantial proportion, over-represented in young-onset cases, have atypical phenotypes …

Clinical trial results presented in 2019 suggest that antibody-based removal of cerebral
amyloid β (Aβ) plaques may possibly clear tau tangles and modestly slow cognitive decline …

We present a consensus atlas of the human brain transcriptome in Alzheimer's disease
(AD), based on meta-analysis of differential gene expression in 2,114 postmortem samples …

Background Alzheimer's disease (AD) is the most common neurodegenerative disorder.
Depositions of amyloid β peptide (Aβ) and tau protein are among the major pathological …

Background Clinicopathological studies suggest that Alzheimer's disease (AD) pathology
begins∼ 10–15 years before the resulting cognitive impairment draws medical attention …

Aetiological and clinical heterogeneity is increasingly recognized as a common
characteristic of Alzheimer's disease and related dementias. This heterogeneity complicates …

Cognitive impairment in the elderly features complex molecular pathophysiology extending
beyond the hallmark pathologies of traditional disease classification. Molecular subtyping …

In the 115 years since the discovery of Alzheimer's disease (AD), our knowledge, diagnosis,
and therapeutics have significantly improved. Biomarkers are the primary tools for clinical …

Background Alzheimer's disease (AD) is a complex multifactorial neurodegenerative
disorder and the most common form of dementia. AD is highly heritable, with heritability …

In Alzheimer's disease, aggregates of Aβ and tau in amyloid plaques and neurofibrillary
tangles spread progressively across brain tissues following a characteristic pattern, implying …